PLG anticorps (N-Term)
-
- Antigène Voir toutes PLG Anticorps
- PLG (Plasminogen (PLG))
-
Épitope
- N-Term
-
Reactivité
- Humain
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp PLG est non-conjugé
-
Application
- Western Blotting (WB), ELISA
- Réactivité croisée
- Humain
- Purification
- The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
- Immunogène
- Synthesized peptide derived from N-terminal of Human PLG.
- Isotype
- IgG
- Top Product
- Discover our top product PLG Anticorps primaire
-
-
- Indications d'application
- WB:1:500-1:3000,
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- -20 °C,-80 °C
- Stockage commentaire
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
- Antigène
- PLG (Plasminogen (PLG))
- Autre désignation
- PLG (PLG Produits)
- Synonymes
- anticorps wu:fb70e09, anticorps PLG, anticorps LPA, anticorps plg, anticorps Ab1-346, anticorps AI649309, anticorps Pg, anticorps plasminogen, anticorps plg, anticorps PLG, anticorps Plg
- Sujet
-
Background: Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells. Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.
Petersen T.E., J. Biol. Chem. 265:6104-6111(1990).
Forsgren M., FEBS Lett. 213:254-260(1987).
Browne M.J., Submitted (OCT-1991) to the EMBL/GenBank/DDBJ databases.Aliases: Plasmin antibody, Plasmin heavy chain A antibody, Plasmin light chain B antibody, Plasminogen antibody, PLG antibody, PLMN_HUMAN antibody
- UniProt
- P00747
- Pathways
- Système du Complément, Lipid Metabolism
-